Anticancer Potential of potent extracts of Bergenia stracheyi

Medicinal plants have been a valuable source of natural products for maintaining human health, especially in the last decade, with more intensive studies for natural therapies. Many plants have been used because of their pharmacological traits, which are due to compounds synthesized in the secondary metabolism of the plant. In the present study, Bergenia stracheyi solvent extracts were screened for anticancer potential against liver (hep-2) cancer cell lines. it was observed that, liver (hep-2) cell line showed 65.78 % cell viability after treatment with  Bergenia stracheyi hydro-alcoholic extract  (20µg/ml) as determined by Trypan blue dye exclusion technique. The cytotoxicity assay of the Bergenia stracheyi hydro-alcoholic extract was determined against liver (hep-2) cell line, 50% cyto-toxicity was observed in 20 µg/ml with respect to hepatic cancer cell line studied. The standard positive drug viz. cyclophosphamide monohydrate showed 50% cyto-toxicity at 10 µg/ml against liver (hep-2) cell line. Thus, the IC50 value of the Bergenia stracheyi hydro-alcoholic extract  was found to be 20µg/ml against hepatic cancer cell lines and IC50 values of cyclophosphamide monohydrate was found to be 10 µg/ml against liver (hep-2) cell line. The Bergenia stracheyi hydro-alcoholic extract  (20µg/ml) was screened against cancer cell lines viz. liver (hep-2) cell line respectively via Sulphorodamine B assay and Microculture tetrazolium (MTT) assay. It was found that the extract was effective against hepatic cancer cell lines studied. It was found that the results of both the tests viz. Sulphorodamine B and MTT assay are correlated to each other.  It was found that, the Bergenia stracheyi hydro-alcoholic extract (20µg/ml) causes 72.56 % inhibition of cancer cells in liver (hep-2) cancer cell line as observed by Sulphorodamine B assay.